Skip to main content
. 2006 Jun 13;94(12):1777–1784. doi: 10.1038/sj.bjc.6603169

Figure 1.

Figure 1

(AC) Overall survival for all eligible patients, NSCLC patients, and breast patients by E-RBC group. The legend for the graphs below is as follows: efaproxiral High E-RBC (solid line), efaproxiral Low E-RBC (dashed line), control (dotted line), censored patients (circles). (A) All patients. (B) NSCLC patients. (C) Breast patients.